Compare LUCY & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUCY | LGVN |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | 13 | N/A |
| Industry | Ophthalmic Goods | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 34.0M |
| IPO Year | N/A | 2021 |
| Metric | LUCY | LGVN |
|---|---|---|
| Price | $0.92 | $0.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 70.0K | ★ 372.7K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $709,000.00 |
| Revenue This Year | $175.92 | N/A |
| Revenue Next Year | $205.56 | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.90 | $0.48 |
| 52 Week High | $2.90 | $1.80 |
| Indicator | LUCY | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 34.59 | 43.60 |
| Support Level | $0.90 | $0.74 |
| Resistance Level | $1.07 | $0.86 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 7.45 | 53.80 |
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok. The firm derive substantially all of its revenue from the sale of smart glasses and custom lenses.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.